title: Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
abstract: The incidence of renal cell carcinoma is increasing globally. Targeted agents offer treatment options that were not available less than a decade ago. However, it is important to carefully select therapy for each individual patient, weighing both the drug efficacy and tolerability profile and patient-related factors, such as adherence, age and comorbidities. Based on our clinical experience in treating patients with renal cell carcinoma, this article offers our opinions on factors that characterize patients for whom sorafenib may serve as a viable first-line therapeutic option.
authors.affiliation: University Hospital del Mar-IMIM, RTICC, Paseo Maritimi 25-29, Barcelona, Spain. jbellmunt@imas.imim.es
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
authors.forename: Mayer
authors.initials: M
authors.lastname: Fishman
authors.forename: Timothy
authors.initials: T
authors.lastname: Eisen
authors.forename: David
authors.initials: D
authors.lastname: Quinn
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib